Intellia Therapeutics provided a clinical update on its in vivo lipid‑nanoparticle (LNP) gene‑editing programs at ESGCT, focusing on NTLA‑2002 and lonvo‑z. CSO Birgit Schultes reported that Intellia has treated more than 350 patients across clinical programs and documented sustained pharmacodynamic effects in liver‑targeted editing studies. Schultes highlighted NTLA‑2002 and lonvo‑z (an in vivo KLKB1 edit for hereditary angioedema), showing durable kallikrein suppression to below ~60% that persisted beyond two years with mainly transient liver enzyme elevations and no serious safety signals reported. She contrasted LNP delivery advantages—transient expression, redosing potential, scalability and reduced germline risk—against viral vectors. The presentation underscores Intellia’s positioning as a leader in systemic in vivo editing and provides clinical evidence for sustained target knockdown using LNP‑delivered editors, information likely to guide regulators and investors evaluating in vivo CRISPR approaches.